Van de Graaff Eric, Dutta Monisha, Das Pranab, Shry Eric A, Frederick Paul D, Blaney Martha, Pasta David J, Steinhubl Steven R
Nebraska Heart Institute, Omaha, Neb, USA.
Stroke. 2006 Oct;37(10):2546-51. doi: 10.1161/01.STR.0000240495.99425.0f. Epub 2006 Sep 7.
Ischemic stroke is an uncommon but devastating complication of myocardial infarction (MI). It is possible that delay in the acute revascularization of these patients influences the risk of peri-MI ischemic stroke independent of size of infarction or residual ventricular function. The influence of the timing and type of revascularization on risk of ischemic stroke in the patient with MI has not previously been assessed.
We used the National Registry of Myocardial Infarction 3 and 4 databases to identify 45,997 subjects who received thrombolytic therapy and 47,876 patients who were treated with primary percutaneous transluminal coronary angioplasty for MI. In-hospital ischemic stroke occurred in 248 (0.54%) and 150 (0.31%) patients in the two groups, respectively. Patients were stratified based on time from presentation to initial therapy.
A statistically significant linear relationship between time to revascularization therapy and risk of in-hospital ischemic stroke was seen on univariate analysis. A multivariate model incorporating 26 other variables showed thrombolytic therapy within 15 minutes was associated with a lower risk of ischemic stroke (odds ratio, 0.58; 95% CI, 0.36-0.94). Primary angioplasty within 90 minutes of arrival was associated with a nonsignificant trend toward lower stroke risk (odds ratio, 0.68; 95% CI, 0.41-1.12). Interestingly, his benefit of early reperfusion therapy did not appear to be related to improvements in left ventricular function.
Risk of in-hospital ischemic stroke with MI is closely tied to the time to revascularization with both thrombolytic and percutaneous transluminal coronary angioplasty therapies. Early revascularization is independently predictive of a lower risk of ischemic stroke, but the mechanism of this does not appear to be related to improved cardiac function. The records of 45,997 subjects who received thrombolytic therapy and 47,876 patients who were treated with primary percutaneous transluminal coronary angioplasty for myocardial infarction were analyzed to determine the relationship between time to revascularization and the occurrence of ischemic stroke. A statistically significant linear relationship between time to revascularization therapy and risk of in-hospital ischemic stroke was seen on univariate analysis. A multivariate model incorporating 26 other variables showed thrombolytic therapy within 15 minutes of presentation was associated with a lower risk of ischemic stroke, and angioplasty within 90 minutes was similarly associated with a nonsignificant trend toward lower stroke risk.
缺血性卒中是心肌梗死(MI)一种不常见但具有毁灭性的并发症。这些患者急性血运重建的延迟可能会影响心肌梗死周围缺血性卒中的风险,而与梗死面积或残余心室功能无关。此前尚未评估血运重建的时机和类型对心肌梗死患者缺血性卒中风险的影响。
我们使用国家心肌梗死注册库3和4数据库,确定了45997例接受溶栓治疗的受试者以及47876例接受直接经皮冠状动脉腔内血管成形术治疗心肌梗死的患者。两组中分别有248例(0.54%)和150例(0.31%)患者发生院内缺血性卒中。根据从就诊到初始治疗的时间对患者进行分层。
单因素分析显示,血运重建治疗时间与院内缺血性卒中风险之间存在统计学显著的线性关系。一个纳入其他26个变量的多变量模型显示,15分钟内进行溶栓治疗与较低的缺血性卒中风险相关(比值比,0.58;95%可信区间为0.36 - 0.94)。到达后90分钟内进行直接血管成形术与较低的卒中风险呈非显著趋势相关(比值比,0.68;95%可信区间为0.41 - 1.12)。有趣的是,早期再灌注治疗的这种益处似乎与左心室功能的改善无关。
心肌梗死患者院内缺血性卒中的风险与溶栓及经皮冠状动脉腔内血管成形术血运重建的时间密切相关。早期血运重建可独立预测较低的缺血性卒中风险,但其机制似乎与心脏功能改善无关。分析了45997例接受溶栓治疗的受试者以及47876例接受直接经皮冠状动脉腔内血管成形术治疗心肌梗死患者的记录,以确定血运重建时间与缺血性卒中发生之间的关系。单因素分析显示,血运重建治疗时间与院内缺血性卒中风险之间存在统计学显著的线性关系。一个纳入其他26个变量的多变量模型显示,就诊后15分钟内进行溶栓治疗与较低的缺血性卒中风险相关,并与90分钟内血管成形术相似地与较低的卒中风险呈非显著趋势相关联。